Table 1.
Clinicopathological characteristics in relation to FASN expression status in 380 ccRCC patients from FUSCC cohort.
| Variable | Entire group (n = 380) | FASN mRNA expression | χ2 | p-value | |
|---|---|---|---|---|---|
| Low expression (n = 190) | High expression (n = 190) | ||||
| Age at surgery (y, median ± SD) | 54.1 ± 12.2 | 56.2 ± 11.4 | |||
| BMI (kg/m2, median ± SD) | 24.5 ± 3.3 | 23.5 ± 8.3 | |||
| Sex (n, %) | 0.012 | 0.914 | |||
| Male | 249 (65.5) | 125 (65.8) | 124 (65.3) | ||
| Female | 131 (34.5) | 65 (34.2) | 66 (34.7) | ||
| Laterality (n, %) | 0.168 | 0.682 | |||
| Left | 190 (50.0) | 97 (51.1) | 93 (48.9) | ||
| Right | 190 (50.0) | 93 (48.9) | 97 (51.1) | ||
| T stage at presentation (n, %) | 16.645 | <0.001 | |||
| T1–T2 | 309 (81.3) | 170 (89.5) | 139 (73.2) | ||
| T3–T4 | 71 (18.7) | 20 (10.5) | 51 (26.8) | ||
| N stage at presentation (n, %) | 5.463 | 0.019 | |||
| N0 | 333 (87.6) | 174 (91.6) | 159 (83.7) | ||
| N1 | 47 (12.4) | 16 (8.4) | 31 (16.3) | ||
| M stage at presentation (n, %) | 2.522 | 0.112 | |||
| M0 | 310 (81.6) | 161 (84.7) | 149 (78.4) | ||
| M1 | 70 (18.4) | 29 (15.3) | 41 (21.6) | ||
| AJCC stage | 9.997 | 0.002 | |||
| I–II | 292 (76.8) | 159 (83.7) | 133 (70.0) | ||
| III–IV | 88 (23.2) | 31 (16.3) | 57 (30.0) | ||
| ISUP grade (n, %) | 0.675 | 0.411 | |||
| 1–2 | 182 (47.9) | 95 (50.0) | 87 (45.8) | ||
| 3–4 | 192 (52.1) | 95 (50.0) | 103 (54.2) | ||
ccRCC, clear cell renal cell carcinoma; FUSCC, Fudan University Shanghai Cancer Center; BMI, body mass index; AJCC, American Joint Committee on Cancer.
*p value less than 0.05 was considered as statistically significant and marked in bold.